Entering text into the input field will update the search result below

Alimera Sciences (ALIM) FDA Oks Diabetic Macular Edema Intravitreal Implant, PSivida (PSDV) Multimillion Dollar Milestone, Nike (NKE) Athletic Trading Session

Sep. 26, 2014 6:25 PM ETALIM, EYPT, NKE
Mike Zaman profile picture
Mike Zaman's Blog
87 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

https://static.seekingalpha.com/uploads/2014/5/5/saupload_crwe_logo.jpg Crown Equity Holdings Inc. (OTCPK:CRWE)

CRWE's goal is to accelerate the success of the company to deliver value for its stockholders in both the near and long term.

The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of website communities.

CRWE has included the city of Syracuse, NY ( www.syracuse.ny.crwe-pr.com ) to the CRWE Network

Syracuse, NY, the fifth most populous city in the state of New York with an estimated population in 2013 (U.S. Census Bureau) of approximately 144,669, represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally

With the addition of Syracuse, NY, the CRWE Network has reached the 1346th community website in the U.S., associated with 3228 ZIP Codes, and includes coverage of the greater state of California, Northern and Southern Nevada, New York State, Wellington in Florida, Hattiesburg in Mississippi and 10 provinces in Canada.

https://static.seekingalpha.com/uploads/2014/9/26/saupload_crwesep26.jpg

https://static.seekingalpha.com/uploads/2014/9/26/saupload_crwetube.jpg Online video is proving to be a powerful marketing tool for many businesses. Strategic plans are being developed for CRWE's division CRWETube ( www.crwetube.com ) to improve the potential future growth for the company.

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com

**

https://static.seekingalpha.com/uploads/2014/9/26/saupload_alim.jpg Alimera Sciences, Inc. (ALIM)

Most of the food we eat is turned into glucose, or sugar, for our bodies to use for energy. The pancreas, an organ that lies near the stomach, makes a hormone called insulin to help glucose get into the cells of our bodies.

Diabetes is the condition in which the body does not properly process food for use as energy. W hen you have diabetes, your body either doesn't make enough insulin or can't use it s own insulin as well as it should. This causes sugars to build up in your blood. This is why many people refer to diabetes as "sugar."

According to the 2014 National Diabetes Statistics Report, 29.1 million people or 9.3% of the population in the United States have diabetes, and 27.8% of people with diabetes are undiagnosed.

Diabetes can be treated and managed by healthful eating, regular physical activity, and medications to lower blood glucose levels. Blood glucose control reduces the risk of developing the eye, nerve, and kidney complications of diabetes

People with diabetes are at an increased risk for developing eye problems. One reason is because diabetes and other complications can cause damage to the blood vessels of the retina (diabetic retinopathy), resulting in vision impairment. Left untreated, these blood vessels begin to build up pressure in the eye and leak fluid, causing Diabetic Macular Edema (DME).

DME, the major cause of vision loss in people with diabetic retinopathy, is an accumulation of fluid in the macula-part of the retina that controls our most detailed vision abilities-due to leaking blood vessels. These leaks cause the macula to thicken and swell, progressively distorting acute vision. While the swelling may not lead to blindness, the effect can cause a severe loss in central vision.

ALIM reported that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN(R) for the treatment of diabetic macular edema (DME). It is indicated for patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).

A single injection of the ILUVIEN micro-insert provides sustained treatment of DME for 36 months. Approximately 560,000 people in the U.S. are estimated to have clinically significant DME, the most frequent cause of vision loss in individuals with diabetes and the leading cause of blindness in young and middle-aged adults in developed countries. ALIM currently intends to begin selling ILUVIEN in the U.S. in the first quarter of 2015..

ILUVIEN is already commercially available in the U.K. and Germany, and has received or is pending marketing approval in seventeen other EU countries, for the treatment of patients with the chronic DME insufficiently responsive to available therapies.

https://static.seekingalpha.com/uploads/2014/9/26/saupload_alim.png

ALIM is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

More about Alimera Sciences, Inc. (ALIM) at www.alimerasciences.com

https://static.seekingalpha.com/uploads/2014/9/26/saupload_psdv.jpg pSivida Corp (PSDV)

FDA approval of ILUVIEN entitles PSDV to a $25 million milestone from its licensee Alimera Sciences. PSDV will also be entitled to 20% of the net profits from sales of ILUVIEN in the U.S.

https://static.seekingalpha.com/uploads/2014/9/26/saupload_psdvch.png

PSDV is a leader in the development of sustained release, drug delivery products for treating eye diseases

More about pSivida Corp. (PSDV) at www.psivida.com

**

https://static.seekingalpha.com/uploads/2014/9/26/saupload_nke.jpg Nike, Inc. (NKE)

Fiscal year 2015 is off to a strong start for NKE, its shares are trading at all-time high levels and, according to the company, it has never been better positioned to realize its tremendous growth potential. NKE reported a solid performance on its financial results, driven by strong demand for NIKE, Inc. brands

For its fiscal 2015 first quarter, NKE posted revenues of $8.0 billion, representing a 15% increase year over year, net income of $962 million, a 23% increase compared to the same period the prior year, and diluted earnings per share increased 27% to $1.09, versus fiscal 2014 first quarter.

Brokerage firm Janney has upgraded NKE stock from Neutral to Buy and raised its price target from $80.00 to $93.00 per share, and several research firms raised their price target while reiterating their view on the company, like Stifel from $89.00 to $100.00 per share with a Buy rating, Telsey Advisory Group from $91.00 to $96.00 per share with an Outperform rating, DA Davidson from $85.00 to $96.00 per share with a Neutral rating, Canaccord Genuity from $76.00 to $88.00 per share with a Hold rating, Deutsche Bank from $90.00 to $95.00 per share with a Buy rating and Barclays from $90.00 to $100.00 per share with an Overweight rating on NKE stock

https://static.seekingalpha.com/uploads/2014/9/26/saupload_nkech.png

NKE is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities.

More about Nike, Inc. (NKE) at www.nikeinc.com

**

Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer

Analyst's Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You